Dr. Craig Campbell is the Deputy Chair of Pediatrics (Research), the Head of the Division of Pediatric Neurology and the medical director of the multidisciplinary neuromuscular clinic based at Thames Valley Children’s Centre and the Pediatric Neurophysiology Laboratory at Children’s Hospital London Health Sciences Centre. He is an Associate Professor in Pediatrics, Clinical Neurological Sciences and Epidemiology at Western University and a Scientist at the Children’s Health Research Institute. His training in Pediatrics and Neurology and Epidemiology was completed at the University of Ottawa.
The pediatric NM service at LHSC/TVCC has evolved into an internationally recognized site for clinical care delivery, research and clinical outcomes evaluation. Clinical trial work in DMD patients has been an area of academic activity, and Dr. Campbell is collaboratively involved in many academic and industry initiated clinical trial activities in pediatric neuromuscular disease. He is a member of the Muscle Study Group, World Muscle Society, and co-chair of the TREAT-NMD Registry Oversight Committee and Task Force. Dr. Campbell has been awarded the George Karpati Award Researcher of the Year in 2011 and 2015, Muscular Dystrophy Canada.
The following are specific areas of innovation:
Congenital Myotonic Dystrophy. The study of CDM has been an interest at a population level and in understanding patient reported outcome measures. We are currently involved in following a cohort of children with CDM who were identified in an active national surveillance program. We have published disease incidence from the surveillance, and compared registry methodology in this population. We are now involved in outcome measurement validation in CDM patient in anticipation of clinical trials.
Development of Canadian Neuromuscular Disease Registry I have also been instrumental in the initiation of the Canadian Neuromuscular Disease Registry as the Pediatric Lead investigator and the past head and founder of the Canadian Pediatric Neuromuscular Group. The CNDR has taken a novel approach to rare disease registry methodology and is now nearing 3000 patients enrolled across Canada. The CNDR data feeds into a global NM disease registry effort coordinated by TREAT-NMD.
Study of Quality of Life in Duchenne Muscular Dystrophy. This more recent line of research has been focused on understanding QOL, HRQOL and fatigue in DMD patients. Our work is the first longitudinal study of QOL using a large patient registry and to approach understanding of QOL using a multivariate approach. Fatigue is emerging as an important factor that impacts QOL and HRQOL and our group is one of the first to explore the role of fatigue in the DMD as an important outcome measure and a potentially modifiable factor to improve patient care.
Founder of the Canadian Pediatric Neuromuscular Group. This academic group, which includes all major pediatric NM centres across Canada, has worked together to understand NM care patterns in Canada and work on collaborative research efforts. The CPNG now functions as an academic network and promoting NM issues in Canada.